mumbai 07 17, 2012, 17:30 IST
The Sensex ended flat, extending its recent weakness as investors sold recent outperformers such as Tata Consultancy and bought defensive stocks such as ITC due to uncertainty about monsoon rainfalls and the prospect of policy reforms.
Pharmaceuticals shares also gained, as investors bet on solid April-June earnings. Dr Reddy's Laboratories
Also Read
The Sensex is down 1.9 percent in July as low rainfalls during the monsoon raise fears about rural consumption, while investors hope for fiscal consolidation or growth-boosting measures after the presidential elections on Thursday.
(To read - Lack of monsoon rain may not mean stocks pain, click http://in.reuters.com/article/2012/07/17/market-eye-lack-of-indian-monsoon-rain-m-idINDEE86G06O20120717)
An improvement in sentiment on either front could help stocks recover quickly, analysts said.
"The downside risk for the market from here is limited and we may see an uptick in coming week mainly on back of reasonable performance on the earnings front and on optimism that post presidential election we may see some policy action" said Sunil Jain, head of equity research at brokerage Nirmal Bang.
"Anyhow currently valuations are not so expensive they are attractive at this level," Jain added.
The Sensex rose 0.01 percent to 17,105.30 points, almost matching its lowest close this month hit in the previous session.
The Nifty lost 0.08 percent to end at 5,192.85 points.
Shares in IT services exporter Tata Consultancy Services
Airline stocks dropped on media reports state-owned oil companies have raised aviation turbine fuel prices by about 1.7 percent to account for higher crude prices.
Jet Airways
Exide Industries
Jindal Steel and Power
However, defensive stocks shone on Tuesday with cigarette maker ITC
Shares in major drug makers, another defensive sector, gained, helped as well by expectations for strong April-June earnings.
A weaker rupee could improve returns from drug exports, and the sector should benefit from exclusive rights to sell some drugs in the key United States market, analysts said.
Dr Reddy's Laboratories